Millions of people in both developed and developing countries are living longer, more productive lives due, in part, to better healthcare and easier access to innovative medicines and vaccines.
Better healthcare, in combination with a myriad of technological advances, is also helping to improve the economic circumstances of many individuals and countries. Some people are still excluded as a result of poverty, lack of education, discrimination and other complex factors.
For more information on our approach to access, click here.
KEY PERFORMANCE INDICATORS1
|Research & Development||2011||2012||2013||2014|
|Top 20 global burdens of illness addressed by our products and pipeline2||53%||55%||88%||88%|
|GCP/PV audits by regulatory agencies or clinical trial investigators that led to significant fines, penalties, warning letters or product seizures||0||0||0||0|
|Established significant external licenses and collaborations3||52||61||40||35|
|Narrative of compounds provided to product development partnerships4||Online||Online||Online||Online|
|Manufacturing & Supply||2011||2012||2013||2014|
|Annual percentage of units manufactured/sold and recalled during a given year (recall rate globally)5||NR||0.19%||0.11%||0.22%|
|Number of local and regional manufacturing partnerships to enable access6||130||84||68||104|
|Number of products available by local and regional partnerships6||NA||34||354||499|
|New product and devices registrations7,8,9||179||204||179||176|
|Local regulatory agency GCP/PV training requests fulfilled that will help strengthen agency capabilities in agencies' GCP/PV-compliance-in-oversight role10||Online||Online||Online||Online|
|Products submitted that have achieved WHO prequalification||10||10||11||11|
|Number of our products that are supported with differential pricing11,12,13||NA||NA||24||35|
|Number of low- and lower-middle-income countries where inter- and/or intra-country pricing has been implemented11,14||NA||NA||70||114|
|Investment in patient- and provider-education programs15||$97.8M||$71.4M||$61.3M||$52.3M|
|Healthcare workers trained through major programs and partnerships16||52,000||38,000||22,000||137,000|
|Investment in partnerships for activities to address underlying barriers to health, such as health-system strengthening and capacity-building17||$35M||$24M||$24M||$32M|
|People reached through our major programs and partnerships18||273M||269M||302M||267M|
|NA: Not available. NR: Not reported. |
1 Data for Access to Health are reflective of our Human Health business only; information on our Animal Health business is reported separately.
2 As defined by the Institute for Health Metrics and Evaluation (IHME), which replaces for 2013 the previously used WHO chart of leading causes of disease, condition or injury.
3 Candidates in our company’s research pipeline or under regulatory review are as of February 20, 2015, as reported in the U.S. Securities and Exchange Commission for 10-K, page 16, filed on February 27, 2015. This includes candidates in Phase II, Phase III, or under regulatory review as of February 20, 2015. As candidates attain regulatory approval, they are removed from this pipeline view.
4 For information on product-development partnerships, visit the “Partnerships” tab at http://www.msdresponsibility.com/access-to-health/research-development/#tab-5591a965c9e82
5 Beginning in 2014, this figure includes recalls within our Animal Health business.
6 Previously, we reported products available through specific agreements, but we have now expanded our reporting to all of our products, including the various strengths and presentations that are sold or distributed through a partnership in local markets, to more accurately reflect our efforts to address local needs.
7 Data include new products and new indications.
8 Data for all years have been updated based on a tracking-system upgrade that corrected miscounts in prior years.
9 For information on new registrations by region, visit http://www.msdresponsibility.com/access-to-health/research-development/clinical-research/#tab-5591b7745c6c4
10 For information on local regulatory agency GCP/PV training requests, visit http://www.msdresponsibility.com/access-to-health/research-development/clinical-research/
11 In 2013, we modified our Key Performance Indicators for differential pricing so that we can more broadly capture and accurately reflect our support.
12 Differential pricing intended to facilitate access for the at-need population.
13 Our products include HIV treatments, vaccines and other patented products.
14 Countries as defined by the World Bank 2013 GNI Classification, including UN-defined Least Developed Countries.
15 In 2013, we refined our support to prioritize and align resources to complement our core business strategy, which resulted in an overall decrease in funding.
16 2014 figure includes healthcare workers trained through the African Programme for Onchocerciasis Control, of which we are a major funder.
17Includes investments by the Office of Corporate Responsibility, MSD for Mothers and/or our company's Foundation, a U.S.-based, private foundation.
18 2013 figures have been reconciled to reflect revised field data for the MECTIZAN Donation Program.